Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Liver Diseases

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 171 articles:
HTML format
Text format



Single Articles


    November 2019
  1. HORIUCHI T, Haruki K, Shiba H, Sakamoto T, et al
    Assessment of Outcome of Hepatic Resection for Extremely Elderly Patients With a Hepatic Malignancy.
    Anticancer Res. 2019;39:6325-6332.
    PubMed     Text format     Abstract available


  2. HO ML, Kuo WK, Chu LJ, Yeh IH, et al
    N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies.
    Anticancer Res. 2019;39:6317-6324.
    PubMed     Text format     Abstract available


  3. OHTA S, Morine Y, Imura S, Ikemoto T, et al
    Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1alpha for Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:6025-6033.
    PubMed     Text format     Abstract available


  4. OGASAWARA S, Mihara Y, Kondo R, Kusano H, et al
    Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo.
    Anticancer Res. 2019;39:5973-5982.
    PubMed     Text format     Abstract available


  5. ENDO M, Kanda M, Sawaki K, Shimizu D, et al
    Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.
    Anticancer Res. 2019;39:5903-5910.
    PubMed     Text format     Abstract available


    October 2019
  6. MARUKUCHI R, Furukawa K, Iwase R, Yasuda J, et al
    Risk Factors for Deterioration of Remnant Liver Function After Hepatic Resection for Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:5755-5760.
    PubMed     Text format     Abstract available


  7. SATO N, Beppu T, Kinoshita K, Yuki H, et al
    Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
    Anticancer Res. 2019;39:5695-5701.
    PubMed     Text format     Abstract available


  8. LIANG J, Ariizumi SI, Nakano M, Yamamoto M, et al
    Diabetes Mellitus and/or Nonalcoholic Steatohepatitis-related Hepatocellular Carcinoma Showed Favorable Surgical Outcomes After Hepatectomy.
    Anticancer Res. 2019;39:5639-5643.
    PubMed     Text format     Abstract available


  9. ZAIMOKU R, Miyashita T, Tajima H, Takamura H, et al
    Monitoring of Heat Shock Response and Phenotypic Changes in Hepatocellular Carcinoma After Heat Treatment.
    Anticancer Res. 2019;39:5393-5401.
    PubMed     Text format     Abstract available


  10. HUNG YH, Lin YC, Lin YT, Shih GW, et al
    Therapeutic Efficacy and Radiobiological Effects of Boric Acid-mediated BNCT in a VX2 Multifocal Liver Tumor-bearing Rabbit Model.
    Anticancer Res. 2019;39:5495-5504.
    PubMed     Text format     Abstract available


    September 2019
  11. TAKAHASHI A, Moriguchi M, Seko Y, Ishikawa H, et al
    Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:5149-5156.
    PubMed     Text format     Abstract available


  12. HORIUCHI T, Haruki K, Shiba H, Sakamoto T, et al
    Assessment of Outcome of Hepatic Resection for Extremely Elderly Patients With a Hepatic Malignancy.
    Anticancer Res. 2019;39:5143-5148.
    PubMed     Text format     Abstract available


  13. AKAZAWA Y, Kono H, Hara M, Furuya S, et al
    M-CSF Receptor Antagonists Inhibit the Initiation and Progression of Hepatocellular Carcinoma in Mice.
    Anticancer Res. 2019;39:4787-4794.
    PubMed     Text format     Abstract available


  14. MORINE Y, Ikemoto T, Iwahashi S, Saito YU, et al
    Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis.
    Anticancer Res. 2019;39:5089-5096.
    PubMed     Text format     Abstract available


  15. SHIBUTANI M, Nagahara H, Fukuoka T, Iseki Y, et al
    Efficacy of Adjuvant Chemotherapy According to the Classification of Recurrence Risk Based on Systemic Inflammatory Markers in Patients With Liver Metastases of Colorectal Cancer.
    Anticancer Res. 2019;39:5039-5045.
    PubMed     Text format     Abstract available


  16. OSHIRO H, Tome Y, Kiyuna T, Yoon SN, et al
    Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer Res. 2019;39:4667-4671.
    PubMed     Text format     Abstract available


    August 2019
  17. AMISAKI M, Yagyu T, Uchinaka EI, Morimoto M, et al
    Prognostic Value of DEPDC1 Expression in Tumor and Non-tumor Tissue of Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:4423-4430.
    PubMed     Text format     Abstract available


  18. SAKURAOKA Y, Kubota K, Imura J, Yamagishi H, et al
    Microsatellite Analysis of Recurrent Lesions Confirms Merit of Anatomical Liver Resection for Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:4315-4324.
    PubMed     Text format     Abstract available


  19. ARIIZUMI SI, Ban D, Abe Y, Kumamoto T, et al
    High-signal-intensity MR Image in the Hepatobiliary Phase Predicts Long-term Survival in Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:4219-4225.
    PubMed     Text format     Abstract available


  20. HISAKA T, Ishikawa H, Sakai H, Kawahara R, et al
    Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis.
    Anticancer Res. 2019;39:4549-4554.
    PubMed     Text format     Abstract available


  21. YOON SN, Park JH, Lwin TM, Miyake K, et al
    Tumor-sealing Surgical Orthotopic Implantation of Human Colon Cancer in Nude Mice Induces Clinically-relevant Metastases Without Early Peritoneal Carcinomatosis.
    Anticancer Res. 2019;39:4065-4071.
    PubMed     Text format     Abstract available


  22. SATAKE T, Suetsugu A, Nakamura M, Kunisada T, et al
    Color-coded Imaging of the Fate of Cancer-cell-derived Exosomes During Pancreatic Cancer Metastases in a Nude-mouse Model.
    Anticancer Res. 2019;39:4055-4060.
    PubMed     Text format     Abstract available


    July 2019
  23. SUNG PS, Yang K, Bae SH, Oh JS, et al
    Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:3909-3916.
    PubMed     Text format     Abstract available


  24. WU TK, Chen CH, Pan YR, Hu CW, et al
    Cetrimonium Bromide Inhibits Cell Migration and Invasion of Human Hepatic SK-HEP-1 Cells Through Modulating the Canonical and Non-canonical TGF-beta Signaling Pathways.
    Anticancer Res. 2019;39:3621-3631.
    PubMed     Text format     Abstract available


  25. NAMGUNG Y, Kim SY, Kim I
    Down-regulation of Survivin by BIX-01294 Pretreatment Overcomes Resistance of Hepatocellular Carcinoma Cells to TRAIL.
    Anticancer Res. 2019;39:3571-3578.
    PubMed     Text format     Abstract available


  26. VUJIC J, Schollnast H, Marsoner K, Wienerroither V, et al
    Marking Disappearing Colorectal Liver Metastases After Complete Response to Neoadjuvant Chemotherapy via CT - A Pilot Study.
    Anticancer Res. 2019;39:3847-3854.
    PubMed     Text format     Abstract available


  27. CROWLEY E, Rowan NJ, Faller D, Friel AM, et al
    Natural and Synthetic Isothiocyanates Possess Anticancer Potential Against Liver and Prostate Cancer In Vitro.
    Anticancer Res. 2019;39:3469-3485.
    PubMed     Text format     Abstract available


    June 2019
  28. SAKATA K, Yoshizumi T, Izumi T, Shimokawa M, et al
    The Role of DNA Repair Glycosylase OGG1 in Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:3241-3248.
    PubMed     Text format     Abstract available


  29. SAITO R, Amemiya H, Hosomura N, Kawaida H, et al
    Prognostic Factors for Post-recurrent Survival in Hepatocellular Carcinoma After Curative Resection.
    Anticancer Res. 2019;39:3033-3038.
    PubMed     Text format     Abstract available


  30. LEE T, Park CK, Ha SY
    Prognostic Role of Apelin Receptor Expression in Hepatocellular Carcinoma Treated With Curative Surgical Resection.
    Anticancer Res. 2019;39:3025-3031.
    PubMed     Text format     Abstract available


  31. ZANG W, Bian H, Huang X, Yin G, et al
    Traditional Chinese Medicine (TCM) Astragalus Membranaceus and Curcuma Wenyujin Promote Vascular Normalization in Tumor-derived Endothelial Cells of Human Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:2739-2747.
    PubMed     Text format     Abstract available


  32. TAKAGI C, Kikuchi Y, Shirakawa H, Hoshimoto S, et al
    Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer.
    Anticancer Res. 2019;39:3177-3183.
    PubMed     Text format     Abstract available


  33. MOKKARALA M, Noda C, Malone C, Ramaswamy R, et al
    Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Versus Radioembolization (TARE) for Patients With Colorectal Cancer Liver Metastases.
    Anticancer Res. 2019;39:3071-3077.
    PubMed     Text format     Abstract available


  34. ISHIKAWA D, Takasu C, Kashihara H, Nishi M, et al
    The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.
    Anticancer Res. 2019;39:2855-2860.
    PubMed     Text format     Abstract available


    May 2019
  35. NAKAO Y, Yamashita YI, Arima K, Miyata T, et al
    Clinical Usefulness of Perioperative C-reactive Protein/Albumin Ratio in Patients With Intrahepatic Cholangiocarcinoma: A Retrospective Single Institutional Study.
    Anticancer Res. 2019;39:2641-2646.
    PubMed     Text format     Abstract available


  36. OMARI J, Heinze C, Damm R, Hass P, et al
    Radioablation of Hepatic Metastases from Renal Cell Carcinoma With Image-guided Interstitial Brachytherapy.
    Anticancer Res. 2019;39:2501-2508.
    PubMed     Text format     Abstract available


  37. UNO S, Sakai M, Fujinari Y, Hosono T, et al
    Diallyl Trisulfide Enhances Benzo[a]pyrene-induced CYP1A1 Expression and Metabolic Activation in Hepatic HepG2 Cells.
    Anticancer Res. 2019;39:2369-2375.
    PubMed     Text format     Abstract available


  38. WENDLING-KEIM D, Vokuhl C, Walz C, Rieder L, et al
    Activation of Hedgehog Signaling in Aggressive Hepatic Hemangioma in Newborns and Infants.
    Anticancer Res. 2019;39:2351-2360.
    PubMed     Text format     Abstract available


    April 2019
  39. KIM SS, Eun JW, Cho HJ, Lee HY, et al
    Effect of Fibroblast Growth Factor-2 and its Receptor Gene Polymorphisms on the Survival of Patients With Hepatitis B Virus-associated Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:2217-2226.
    PubMed     Text format     Abstract available


  40. NAGAI H, Mukozu T, Kobayashi K, Amanuma M, et al
    Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology.
    Anticancer Res. 2019;39:2183-2191.
    PubMed     Text format     Abstract available


  41. MIYATA T, Beppu T, Imamura YU, Hayashi H, et al
    A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
    Anticancer Res. 2019;39:2139-2144.
    PubMed     Text format     Abstract available


  42. YAMADA M, Yamamoto Y, Sugiura T, Kakuda Y, et al
    Comparison of the Clinicopathological Features in Small Bile Duct and Bile Ductular Type Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:2121-2127.
    PubMed     Text format     Abstract available


  43. ZHENG B, Yang S, Tian Q, Xie Y, et al
    Delivery of Antisense Oligonucleotide LOR-2501 Using Transferrin-conjugated Polyethylenimine-based Lipid Nanoparticle.
    Anticancer Res. 2019;39:1785-1793.
    PubMed     Text format     Abstract available


    March 2019

  44. Hepatic Stem Cells.
    Anticancer Res. 2019;39:1631.
    PubMed     Text format    


  45. SCHNAPAUFF D, Tegel BR, Powerski MJ, Colletini F, et al
    Interstitial Brachytherapy in Combination With Previous Transarterial Embolization in Patients With Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:1329-1336.
    PubMed     Text format     Abstract available


  46. XU X, Gao D, Yuan X, Liu LI, et al
    beta-Catenin Expression Correlates With Prognosis in Hepatocellular Carcinoma Patients Treated With Transcatheter Arterial Chemoembolization.
    Anticancer Res. 2019;39:1129-1134.
    PubMed     Text format     Abstract available


  47. NISHIE A, Akahori S, Asayama Y, Ishigami K, et al
    Prediction of Liver Fibrosis Using CT Under Respiratory Control: New Attempt Using Deformation Vectors Obtained by Non-rigid Registration Technique.
    Anticancer Res. 2019;39:1417-1424.
    PubMed     Text format     Abstract available


  48. ORTEGA-GRANADOS AL, Artal-Cortes A, Aguiar-Bujanda D, Oramas J, et al
    Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1317-1328.
    PubMed     Text format     Abstract available


  49. YANO Y, Yoshimatsu K, Yokomizo H, Sagawa M, et al
    Enhancement of the Marginal Area in Colorectal Cancer Liver Metastasis on Computed Tomography Correlates With Microvessel Density and Clinicopathological Factors.
    Anticancer Res. 2019;39:1301-1308.
    PubMed     Text format     Abstract available


  50. KEMPER M, Strohm T, Grupp K, Ghadban T, et al
    Increase of CD45-positive Immune Cells in Liver Parenchyma Indicates a More Favorable Prognosis for Patients With Barrett's Cancer.
    Anticancer Res. 2019;39:1191-1196.
    PubMed     Text format     Abstract available


    February 2019
  51. HARIMOTO N, Hoshino K, Muranushi R, Hagiwara K, et al
    Impact of Metabolic Parameters of (18)F-Fluorodeoxyglucose Positron-emission Tomography After Hepatic Resection in Patients With Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:971-977.
    PubMed     Text format     Abstract available


  52. ARIMA K, Nitta H, Beppu T, Nakagawa S, et al
    Impact of Repeated Hepatectomy on Liver Regeneration in Hepatocellular Carcinoma: A Propensity Score-based Analysis.
    Anticancer Res. 2019;39:965-970.
    PubMed     Text format     Abstract available


  53. WATANABE A, Harimoto N, Araki K, Kubo N, et al
    Absolute Neutrophil Count Predicts Postoperative Prognosis in Mass-forming Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:941-947.
    PubMed     Text format     Abstract available


  54. YAMAO T, Yamashita YI, Imai K, Umezaki N, et al
    Clinical Significance of Preoperative Hepatocellular Carcinoma With High Lens culinaris Agglutinin-reactive Fraction of Alpha-Fetoprotein, But Low Alpha-Fetoprotein.
    Anticancer Res. 2019;39:883-889.
    PubMed     Text format     Abstract available


  55. CHEN JY, Huang WC, Wei CT, Chien PH, et al
    The C-Terminus of Hepatitis B Virus-encoded X Protein Is Required for Lapatinib Sensitivity in Hepatocellular Carcinoma Cells.
    Anticancer Res. 2019;39:721-726.
    PubMed     Text format     Abstract available


  56. WEI CT, Chen LC, Hsiang YP, Hung YJ, et al
    Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.
    Anticancer Res. 2019;39:695-701.
    PubMed     Text format     Abstract available


  57. UMEZAKI N, Hashimoto D, Yamashita YI, Nakagawa S, et al
    Neuroendocrine Tumor of the Hilar Bile Duct.
    Anticancer Res. 2019;39:903-907.
    PubMed     Text format     Abstract available


    January 2019
  58. SEO S, Yoh T, Morino K, Fuji H, et al
    The Relationship Between (18)F-FDG Uptake on PET/CT and Markers of Systemic Inflammatory Response in Patients Undergoing Surgery for Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:341-346.
    PubMed     Text format     Abstract available


    December 2018
  59. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    SMARCB1/INI1 Is Diagnostically Useful in Distinguishing alpha-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6865-6868.
    PubMed     Text format     Abstract available


  60. WU CY, Jan YJ, Ko BS, Wu YJ, et al
    Prognostic Significance of 14-3-3epsilon, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6855-6863.
    PubMed     Text format     Abstract available


  61. VALAKH V, Gresswell S, Kirichenko A
    Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant.
    Anticancer Res. 2018;38:6815-6820.
    PubMed     Text format     Abstract available


  62. WAKIYAMA H, Masuda T, Motomura Y, Hu Q, et al
    Cytolytic Activity (CYT) Score Is a Prognostic Biomarker Reflecting Host Immune Status in Hepatocellular Carcinoma (HCC).
    Anticancer Res. 2018;38:6631-6638.
    PubMed     Text format     Abstract available


    November 2018
  63. TOSHIMA T, Yoshizumi T, Ikegami T, Harada N, et al
    Impact of Osteopenia in Liver Cirrhosis: Special Reference to Standard Bone Mineral Density with Age.
    Anticancer Res. 2018;38:6465-6471.
    PubMed     Text format     Abstract available


  64. SO S, Komatsu S, Takebe A, Kido M, et al
    Novel Extracorporeal Hemoperfusion System for Hepatic Arterial Infusion of Cisplatin.
    Anticancer Res. 2018;38:6445-6452.
    PubMed     Text format     Abstract available


  65. XU J, Noda C, Erickson A, Mokkarala M, et al
    Radiofrequency Ablation vs. Cryoablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study.
    Anticancer Res. 2018;38:6381-6386.
    PubMed     Text format     Abstract available


  66. MASUDA T, Margonis GA, Andreatos N, Wang J, et al
    Combined Hepatic Resection and Radio-frequency Ablation for Patients with Colorectal Cancer Liver Metastasis: A Viable Option for Patients with a Large Number of Tumors.
    Anticancer Res. 2018;38:6353-6360.
    PubMed     Text format     Abstract available


  67. MASUISHI T, Taniguchi H, Eto T, Komori A, et al
    Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases.
    Anticancer Res. 2018;38:6501-6506.
    PubMed     Text format     Abstract available


  68. PALKOVICS A, Vereczkei A, Kalmar KN, Fincsur A, et al
    The Issue of Survival After Colorectal Liver Metastasis Surgery: Parenchyma Sparing vs. Radicality.
    Anticancer Res. 2018;38:6431-6438.
    PubMed     Text format     Abstract available


    October 2018
  69. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Text format     Abstract available


  70. COLLOT T, Fumet JD, Klopfenstein Q, Vincent J, et al
    Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
    Anticancer Res. 2018;38:5963-5968.
    PubMed     Text format     Abstract available


  71. TAKAMORI S, Takada K, Toyokawa G, Azuma K, et al
    PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5897-5901.
    PubMed     Text format     Abstract available


  72. SUGIYAMA K, Narita Y, Mitani S, Honda K, et al
    Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
    Anticancer Res. 2018;38:5859-5866.
    PubMed     Text format     Abstract available


    September 2018
  73. JIANG P, Gu L, Zhou Y, Zhao Y, et al
    Synchronous Laryngeal Squamous Cell Carcinoma and Intrahepatic Cholangiocarcinoma Present in an Obese Male with Poor Prognosis.
    Anticancer Res. 2018;38:5547-5550.
    PubMed     Text format     Abstract available


  74. SANO S, Yamamoto Y, Sugiura T, Okamura Y, et al
    The Radiological Differentiation of Hypervascular Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma with a Focus on the CT Value on Multi-phase Enhanced CT.
    Anticancer Res. 2018;38:5505-5512.
    PubMed     Text format     Abstract available


  75. JORDAN F, Grundmann N, Schenkirsch G, Markl B, et al
    Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
    Anticancer Res. 2018;38:5539-5546.
    PubMed     Text format     Abstract available


  76. TRESKA V, Fichtl J, Ludvik J, Bruha J, et al
    Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases.
    Anticancer Res. 2018;38:5531-5537.
    PubMed     Text format     Abstract available


  77. HEINZE C, Omari J, Othmer M, Hass P, et al
    Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma.
    Anticancer Res. 2018;38:5401-5407.
    PubMed     Text format     Abstract available


  78. KAWAHARA H, Yoshida S, Tohyama Y, Yanagisawa S, et al
    Serum Carcinoembryonic Antigen Levels Before the First Curative Hepatectomy for Metastatic Colorectal Cancer Is a Predictor of Recurrence.
    Anticancer Res. 2018;38:5351-5355.
    PubMed     Text format     Abstract available


    August 2018
  79. HARIMOTO N, Hoshino H, Muranushi R, Hagiwara K, et al
    Skeletal Muscle Volume and Intramuscular Adipose Tissue Are Prognostic Predictors of Postoperative Complications After Hepatic Resection.
    Anticancer Res. 2018;38:4933-4939.
    PubMed     Text format     Abstract available


  80. YU JI, Choi GS, Lim DH, Lee E, et al
    Treatment of Naive HCC Combined with Segmental or Subsegmental Portal Vein Tumor Thrombosis: Liver Resection Versus TACE Followed by Radiotherapy.
    Anticancer Res. 2018;38:4919-4925.
    PubMed     Text format     Abstract available


  81. ROSSI L, Biagioni C, McCartney A, Moretti E, et al
    Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.
    Anticancer Res. 2018;38:4839-4845.
    PubMed     Text format     Abstract available


  82. MORIMOTO M, Honjo S, Sakamoto T, Uchinaka EI, et al
    Pilot Study of Probe-based Confocal Laser Endomicroscopy with Fluorescein-dripping Method for Liver Tumors.
    Anticancer Res. 2018;38:4775-4781.
    PubMed     Text format     Abstract available


  83. SHIROYAMA T, Suzuki H, Tamiya M, Tamiya A, et al
    Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4723-4729.
    PubMed     Text format     Abstract available


    July 2018
  84. UCHIYAMA H, Komatsu KI, Nakata A, Sato K, et al
    Global Liver Gene Expression Analysis on a Murine Hepatic Steatosis Model Treated with Mulberry (Morus alba L.) Leaf Powder.
    Anticancer Res. 2018;38:4305-4311.
    PubMed     Text format     Abstract available


  85. NOH CK, Wang HJ, Kim CM, Kim J, et al
    EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:4101-4109.
    PubMed     Text format     Abstract available


  86. KOGA Y, Beppu T, Miyata T, Kitano Y, et al
    Predicting Poorly Differentiated Hepatocellular Carcinoma that Meets the Milan Criteria.
    Anticancer Res. 2018;38:4093-4099.
    PubMed     Text format     Abstract available


  87. SCHMIDT TM, Liu LI, Abraham IE, Uy AB, et al
    Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:4027-4034.
    PubMed     Text format     Abstract available


  88. TSAI TJ, Chao WY, Chen CC, Chen YJ, et al
    Gelsolin-like Actin-capping Protein (CapG) Overexpression in the Cytoplasm of Human Hepatocellular Carcinoma, Associated with Cellular Invasion, Migration and Tumor Prognosis.
    Anticancer Res. 2018;38:3943-3950.
    PubMed     Text format     Abstract available


  89. INAGAWA H, Saika T, Nishiyama N, Nisizawa T, et al
    Dewaxed Brown Rice Feed Improves Fatty Liver in Obese and Diabetic Model Mice.
    Anticancer Res. 2018;38:4339-4345.
    PubMed     Text format     Abstract available


  90. JELSKI W, Wolszczak-Biedrzycka B, Zasimowicz-Majewska E, Orywal K, et al
    Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease.
    Anticancer Res. 2018;38:4005-4009.
    PubMed     Text format     Abstract available


  91. MIRKA H, Duras P, Baxa J, Korcakova E, et al
    Contribution of Computed Tomographic Angiography to Pretreatment Planning of Radio-embolization of Liver Tumors.
    Anticancer Res. 2018;38:3825-3829.
    PubMed     Text format     Abstract available


    June 2018
  92. SHIBA S, Shibuya K, Katoh H, Koyama Y, et al
    No Deterioration in Clinical Outcomes of Carbon Ion Radiotherapy for Sarcopenia Patients with Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:3579-3586.
    PubMed     Text format     Abstract available


  93. ANDO K, Sakoda M, Ueno S, Hiwatashi K, et al
    Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:3411-3418.
    PubMed     Text format     Abstract available


  94. SAWAZAKI S, Numata M, Morita J, Maezawa Y, et al
    Safety of Laparoscopic Surgery for Colorectal Cancer in Patients with Severe Comorbidities.
    Anticancer Res. 2018;38:3767-3772.
    PubMed     Text format     Abstract available


  95. TRESKA V, Topolcan O, Zoubkova V, Treskova I, et al
    Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases.
    Anticancer Res. 2018;38:3647-3652.
    PubMed     Text format     Abstract available


    May 2018
  96. MACHAIRAS N, Papaconstantinou D, Stamopoulos P, Prodromidou A, et al
    The Emerging Role of Laparoscopic Liver Resection in the Treatment of Recurrent Hepatocellular Carcinoma: A Systematic Review.
    Anticancer Res. 2018;38:3181-3186.
    PubMed     Text format     Abstract available


  97. YOSHIDA M, Beppu T, Shiraishi S, Tsuda N, et al
    Liver Function in Areas of Hepatic Venous Congestion After Hepatectomy for Liver Cancer: (99m)Tc-GSA SPECT/CT Fused Imaging Study.
    Anticancer Res. 2018;38:3089-3095.
    PubMed     Text format     Abstract available


  98. IWABU J, Namikawa T, Tsuda S, Kitagawa H, et al
    Successful Distal Gastrectomy for Gastric Cancer with Child-Pugh Class B Alcoholic Liver Cirrhosis.
    Anticancer Res. 2018;38:3085-3087.
    PubMed     Text format     Abstract available


  99. LAI JZ, Zhou Y, Cao D
    Synchronous Pancreatic Ductal Adenocarcinoma and Hepatocellular Carcinoma: Report of a Case and Review of the Literature.
    Anticancer Res. 2018;38:3009-3012.
    PubMed     Text format     Abstract available


  100. SHIH YL, Huang YH, Lin KH, Chu YD, et al
    Identification of Functional Thyroid Stimulating Hormone Receptor and TSHR Gene Mutations in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:2793-2802.
    PubMed     Text format     Abstract available


  101. HABERL EM, Pohl R, Rein-Fischboeck L, Feder S, et al
    Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
    Anticancer Res. 2018;38:2649-2657.
    PubMed     Text format     Abstract available


  102. ALFONSO PG, Podesta MC, Martin AM, Codeisido MB, et al
    Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
    Anticancer Res. 2018;38:3069-3077.
    PubMed     Text format     Abstract available


  103. CHANG J, Charalel R, Noda C, Ramaswamy R, et al
    Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.
    Anticancer Res. 2018;38:3063-3068.
    PubMed     Text format     Abstract available


  104. DESHWAR A, Margonis GA, Andreatos N, Barbon C, et al
    Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.
    Anticancer Res. 2018;38:2891-2895.
    PubMed     Text format     Abstract available


  105. NASSEREDDINE S, Alsubait S, Tabbara I
    Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances.
    Anticancer Res. 2018;38:2597-2605.
    PubMed     Text format     Abstract available


    April 2018
  106. KANG WH, Tak E, Hwang S, Song GW, et al
    Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From In Vitro to a Clinical Study.
    Anticancer Res. 2018;38:2399-2407.
    PubMed     Text format     Abstract available


  107. TSAI JJ, Hsu FT, Pan PJ, Chen CW, et al
    Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.
    Anticancer Res. 2018;38:2119-2125.
    PubMed     Text format     Abstract available


  108. SATAKE T, Suetsugu A, Nakamura M, Hasegawa K, et al
    Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.
    Anticancer Res. 2018;38:1927-1935.
    PubMed     Text format     Abstract available


    March 2018
  109. TOYA R, Saito T, Shiraishi S, Kai Y, et al
    Dose-function Histogram Evaluation Using (99m)Tc-GSA SPECT/CT Images for Stereotactic Body Radiation Therapy Planning for Hepatocellular Carcinoma Patients: A Dosimetric Parameter Comparison.
    Anticancer Res. 2018;38:1511-1516.
    PubMed     Text format     Abstract available


  110. OKANO N, Kasuga A, Kawai K, Yamauchi Y, et al
    The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
    Anticancer Res. 2018;38:1755-1761.
    PubMed     Text format     Abstract available


  111. FILIPESCU A, Balescu I, Bacalbasa N
    Upper Abdominal Resection for Isolated Metastatic Lesions in Recurrent Cervical Cancer.
    Anticancer Res. 2018;38:1659-1663.
    PubMed     Text format     Abstract available


  112. KINOSHITA K, Beppu T, Miyata T, Kuramoto K, et al
    A Case of 15-Year Recurrence-free Survival After Microwave Coagulation Therapy for Liver Metastasis from Gastric Cancer.
    Anticancer Res. 2018;38:1595-1598.
    PubMed     Text format     Abstract available


  113. MORIS D, Ntanasis-Stathopoulos I, Tsilimigras DI, Vagios S, et al
    Update on Surgical Management of Small Bowel Neuroendocrine Tumors.
    Anticancer Res. 2018;38:1267-1278.
    PubMed     Text format     Abstract available


    February 2018
  114. IMAI K, Yamashita YI, Yusa T, Nakao Y, et al
    Microvascular Invasion in Small-sized Hepatocellular Carcinoma: Significance for Outcomes Following Hepatectomy and Radiofrequency Ablation.
    Anticancer Res. 2018;38:1053-1060.
    PubMed     Text format     Abstract available


  115. TSUKAMOTO M, Yamashita YI, Imai K, Umezaki N, et al
    Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period.
    Anticancer Res. 2018;38:1047-1052.
    PubMed     Text format     Abstract available


  116. SATTLER T, Bredt C, Surwald S, Rust C, et al
    Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 mum for the Treatment of Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:1025-1032.
    PubMed     Text format     Abstract available


  117. UEMOTO K, Doi H, Shiomi H, Yamada K, et al
    Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:945-954.
    PubMed     Text format     Abstract available


  118. HORTON CE, Kamal M, Leslie M, Zhang R, et al
    Circulating Tumor Cells Accurately Predicting Progressive Disease After Treatment in a Patient with Non-small Cell Lung Cancer Showing Response on Scans.
    Anticancer Res. 2018;38:1073-1076.
    PubMed     Text format     Abstract available


  119. OSADA S, Gotoh A, Yokoi R, Tsuchiya H, et al
    Effective Timing of Surgical Resection of Colorectal Cancer Liver Metastases During Chemotherapy.
    Anticancer Res. 2018;38:737-743.
    PubMed     Text format     Abstract available


  120. DOI H, Beppu N, Kitajima K, Kuribayashi K, et al
    Stereotactic Body Radiation Therapy for Liver Tumors: Current Status and Perspectives.
    Anticancer Res. 2018;38:591-599.
    PubMed     Text format     Abstract available


  121. CEAUSU AR, Ciolofan A, Cimpean AM, Magheti A, et al
    The Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin.
    Anticancer Res. 2018;38:811-816.
    PubMed     Text format     Abstract available


    January 2018
  122. KURAMOTO K, Beppu T, Nitta H, Imai K, et al
    Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination.
    Anticancer Res. 2018;38:525-531.
    PubMed     Text format     Abstract available


  123. YOSHIMOTO T, Imura S, Morine Y, Ikemoto T, et al
    The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Anticancer Res. 2018;38:501-507.
    PubMed     Text format     Abstract available


  124. SPELT L, Sasor A, Ansari D, Hilmersson KS, et al
    The Prognostic Role of Cancer Stem Cell Markers for Long-term Outcome After Resection of Colonic Liver Metastases.
    Anticancer Res. 2018;38:313-320.
    PubMed     Text format     Abstract available


  125. VIRGILIO E, Cavallini M
    Managing Focal Nodular Hyperplasia of the Liver: Surgery or Minimally-invasive Approaches? A Review of the Preferable Treatment Options.
    Anticancer Res. 2018;38:33-36.
    PubMed     Text format     Abstract available


    December 2017
  126. TSUKAMOTO M, Yamashita YI, Imai K, Umezaki N, et al
    Predictors of Cure of Intrahepatic Cholangiocarcinoma After Hepatic Resection.
    Anticancer Res. 2017;37:6971-6975.
    PubMed     Text format     Abstract available


  127. LIANG YH, Shao YY, Chen HM, Cheng AL, et al
    Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study.
    Anticancer Res. 2017;37:7095-7104.
    PubMed     Text format     Abstract available


  128. MIYATA T, Beppu T, Higashi T, Nakagawa S, et al
    A Glissonean Approach with Individual Isolation During Right Hemi-Hepatectomy After Portal Vein Embolization.
    Anticancer Res. 2017;37:7069-7071.
    PubMed     Text format     Abstract available


  129. SHIBATA H, Ohike N, Norose T, Isobe T, et al
    Mucinous Cystic Neoplasms Lined by Abundant Mucinous Epithelium Frequently Involve KRAS Mutations and Malignant Progression.
    Anticancer Res. 2017;37:7063-7068.
    PubMed     Text format     Abstract available


  130. CAIVANO D, Valeriani M, Russo I, Bonome P, et al
    Stereotactic Body Radiation Therapy in Primary and Metastatic Liver Disease.
    Anticancer Res. 2017;37:7005-7010.
    PubMed     Text format     Abstract available


    November 2017
  131. BAI YC, Hsia YC, Lin YT, Chen KH, et al
    Effect of Tumor Microenvironment on Selective Uptake of Boric Acid in HepG2 Human Hepatoma Cells.
    Anticancer Res. 2017;37:6347-6353.
    PubMed     Text format     Abstract available


  132. CIRIMBEI C, Rotaru V, Chitoran E, Pavaleanu O, et al
    Immediate and Long-term Results of Radiofrequency Ablation for Colorectal Liver Metastases.
    Anticancer Res. 2017;37:6489-6494.
    PubMed     Text format     Abstract available


  133. SATONAKA H, Ishida K, Takai M, Koide R, et al
    (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways.
    Anticancer Res. 2017;37:6071-6077.
    PubMed     Text format     Abstract available


    October 2017
  134. IMURA S, Yamada S, Saito YU, Iwahashi S, et al
    miR-223 and Stathmin-1 Expression in Non-tumor Liver Tissue of Patients with Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:5877-5883.
    PubMed     Text format     Abstract available


  135. MORINE Y, Imura S, Ikemoto T, Iwahashi S, et al
    CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection.
    Anticancer Res. 2017;37:5701-5705.
    PubMed     Text format     Abstract available


  136. RATHMANN N, Kara K, Budjan J, Henzler T, et al
    Parenchymal Liver Blood Volume and Dynamic Volume Perfusion CT Measurements of Hepatocellular Carcinoma in Patients Undergoing Transarterial Chemoembolization.
    Anticancer Res. 2017;37:5681-5685.
    PubMed     Text format     Abstract available


  137. IKEMOTO T, Shimada M, Ishikawa D, Kawashita Y, et al
    Peripheral Tr1 and Foxp3+ Treg as Markers of Recurrent Malignancies in Patients with Hepato-Biliary Pancreatic Cancers.
    Anticancer Res. 2017;37:5541-5552.
    PubMed     Text format     Abstract available


  138. KISHIMOTO S, Yasuda M, Fukushima S
    Changes in the Expression of Various Transporters as Influencing Factors of Resistance to Cisplatin.
    Anticancer Res. 2017;37:5477-5484.
    PubMed     Text format     Abstract available


    September 2017
  139. SAKABE T, Azumi J, Umekita Y, Toriguchi K, et al
    Expression of Cancer Stem Cell-associated DKK1 mRNA Serves as Prognostic Marker for Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:4881-4888.
    PubMed     Text format     Abstract available


  140. BI YE, Zhou Y, Wang M, Li L, et al
    Targeted Delivery of Cordycepin to Liver Cancer Cells Using Transferrin-conjugated Liposomes.
    Anticancer Res. 2017;37:5207-5214.
    PubMed     Text format     Abstract available


  141. CICERO G, Lo Re G, DE Luca R, Vernuccio F, et al
    Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experience.
    Anticancer Res. 2017;37:5187-5192.
    PubMed     Text format     Abstract available


  142. DIVELLA R, Daniele A, DE Luca R, Simone M, et al
    Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:4867-4871.
    PubMed     Text format     Abstract available


    August 2017
  143. WANG L, Liu M, Liu L, Zheng Y, et al
    MR-guided Percutaneous Biopsy of Focal Hepatic Dome Lesions with Free-hand Combined with MR Fluoroscopy Using 1.0-T Open High-field Scanner.
    Anticancer Res. 2017;37:4635-4641.
    PubMed     Text format     Abstract available


  144. GONG Z, Chi C, Huang X, Chu H, et al
    Cyclophilin A Is Overexpressed in Hepatocellular Carcinoma and Is Associated with the Cell Cycle.
    Anticancer Res. 2017;37:4443-4447.
    PubMed     Text format     Abstract available


  145. ZHANG WG, Yin XC, Liu XF, Meng KW, et al
    Puerarin Induces Hepatocellular Carcinoma Cell Apoptosis Modulated by MAPK Signaling Pathways in a Dose-dependent Manner.
    Anticancer Res. 2017;37:4425-4431.
    PubMed     Text format     Abstract available


    July 2017
  146. HARADA N, Yoshizumi T, Yamashita YI, Soejima Y, et al
    Impact and Prediction of Lymph Node Involvement in Patients with Intrahepatic Cholangiocarcinoma After Curative Resection.
    Anticancer Res. 2017;37:3763-3769.
    PubMed     Text format     Abstract available


  147. KRAUTBAUER S, Weiss TS, Wiest R, Schacherer D, et al
    Diagnostic Value of Systemic Cholesteryl Ester/Free Cholesterol Ratio in Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3527-3535.
    PubMed     Text format     Abstract available


  148. HAYASHI T, Yamashita T, Okada H, Oishi N, et al
    A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3397-3403.
    PubMed     Text format     Abstract available


  149. ISHII F, Yoshida Y, Yamauchi Y, Aisu N, et al
    Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated alphabeta T-cells.
    Anticancer Res. 2017;37:3933-3939.
    PubMed     Text format     Abstract available


  150. SHIBA I, Kouzaki R, Yamada H, Endo Y, et al
    Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase.
    Anticancer Res. 2017;37:3877-3883.
    PubMed     Text format     Abstract available


  151. SETO K, Sakabe T, Itaba N, Azumi J, et al
    A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
    Anticancer Res. 2017;37:3569-3579.
    PubMed     Text format     Abstract available


  152. NAKAMURA M, Suetsugu A, Hasegawa K, Matsumoto T, et al
    Choline-Deficient-Diet-Induced Fatty Liver Is a Metastasis-Resistant Microenvironment.
    Anticancer Res. 2017;37:3429-3434.
    PubMed     Text format     Abstract available


    June 2017
  153. WAKIYAMA S, Matsumoto M, Haruki K, Gocho T, et al
    Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3207-3213.
    PubMed     Text format     Abstract available


  154. MATSUMOTO T, Ichikawa H, Imai J, Hayashi T, et al
    Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3183-3187.
    PubMed     Text format     Abstract available


  155. LIN CL, Chien RN, Liang KH, Ke PY, et al
    Intrahepatic HCV RNA Level and Genotype 1 Independently Associate with Hepatic Reticulon 3 Expression.
    Anticancer Res. 2017;37:2885-2891.
    PubMed     Text format     Abstract available


    May 2017
  156. MIYATA T, Yamashita YI, Yamao T, Umezaki N, et al
    Clinical Benefits of Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: A Retrospective Single-institution Study.
    Anticancer Res. 2017;37:2673-2677.
    PubMed     Text format     Abstract available


  157. HASHIMOTO M, Kobayashi T, Ishiyama K, Ide K, et al
    Predictive Independent Factors for Extrahepatic Metastasis of Hepatocellular Carcinoma Following Curative Hepatectomy.
    Anticancer Res. 2017;37:2625-2631.
    PubMed     Text format     Abstract available


  158. LU LC, Chen PJ, Yeh YC, Hsu CH, et al
    Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
    Anticancer Res. 2017;37:2593-2599.
    PubMed     Text format     Abstract available


  159. KANAJI N, Kita N, Kadowaki N, Bandoh S, et al
    Fibronectin and Hepatocyte Growth Factor Produced by Lung Fibroblasts Augment Migration and Invasion of Malignant Pleural Mesothelioma Cells.
    Anticancer Res. 2017;37:2393-2400.
    PubMed     Text format     Abstract available


  160. BARABINO M, Gatti A, Santambrogio R, Polizzi M, et al
    Intraoperative Local Ablative Therapies Combined with Surgery for the Treatment of Bilobar Colorectal Liver Metastases.
    Anticancer Res. 2017;37:2743-2750.
    PubMed     Text format     Abstract available


    April 2017
  161. MALKI A, El-Sharkawy A, El Syaed M, Bergmeier S, et al
    Antitumor Activities of the Novel Isosteviol Derivative 10C Against Liver Cancer.
    Anticancer Res. 2017;37:1591-1601.
    PubMed     Text format     Abstract available


  162. TAHARA T, Tahara S, Horiguchi N, Kawamura T, et al
    Telomere Length in Leukocyte DNA in Gastric Cancer Patients and its Association with Clinicopathological Features and Prognosis.
    Anticancer Res. 2017;37:1997-2001.
    PubMed     Text format     Abstract available


  163. OTTAIANO A, Capozzi M, DE Divitiis C, VON Arx C, et al
    Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
    Anticancer Res. 2017;37:1975-1978.
    PubMed     Text format     Abstract available


  164. HARADA N, Yoshizumi T, Maeda T, Kayashima H, et al
    Preoperative Pancreatic Stiffness by Real-time Tissue Elastography to Predict Pancreatic Fistula After Pancreaticoduodenectomy.
    Anticancer Res. 2017;37:1909-1915.
    PubMed     Text format     Abstract available


    March 2017
  165. DE PASQUALE MD, de Ville de Goyet J, Monti L, Grimaldi C, et al
    Bevacizumab Combined with Chemotherapy in Children Affected by Hepatocellular Carcinoma: a Single-center Experience.
    Anticancer Res. 2017;37:1489-1493.
    PubMed     Text format     Abstract available


  166. ITOH S, Uchiyama H, Ikeda Y, Morita K, et al
    Post-hepatectomy Refractory Ascites in Cirrhotic Patients with Hepatocellular Carcinoma: Risk Factor Analysis to Overcome this Problematic Complication.
    Anticancer Res. 2017;37:1381-1385.
    PubMed     Text format     Abstract available


  167. MARQUES LA, Semprebon SC, Sartori D, DE Fatima A, et al
    Comparison of the Effects of Monastrol and Oxomonastrol on Human Hepatoma Cell Line HepG2/C3A.
    Anticancer Res. 2017;37:1197-1204.
    PubMed     Text format     Abstract available


  168. YOSHIKAWA M, Morine Y, Ikemoto T, Imura S, et al
    Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:1169-1175.
    PubMed     Text format     Abstract available


  169. KOMATSU H, Masuda T, Iguchi T, Nambara S, et al
    Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:1083-1090.
    PubMed     Text format     Abstract available


  170. TRESKA V, Fichtl J, Bruha J, Liska V, et al
    Liver Resections for Colorectal Metastases in Patients Aged Over 75 Years.
    Anticancer Res. 2017;37:1529-1533.
    PubMed     Text format     Abstract available


  171. D'ONOFRIO M, Cingarlini S, Ortolani S, Crosara S, et al
    Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.
    Anticancer Res. 2017;37:1305-1311.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: